Nilotinib dihydrochloride dihydrate

Nilotinib dihydrochloride dihydrate is the clinically used salt form of nilotinib, a tyrosine kinase inhibitor (TKI). It is mainly used to treat Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in both chronic and accelerated phases. This form enhances the stability, solubility, and bioavailability of nilotinib for oral administration. Like the base compound, it works by selectively inhibiting the BCR-ABL fusion protein, helping to control the proliferation of malignant white blood cells. It is grouped under the following drug class(es): Antineoplastic agents. Its therapeutic use is listed as antineoplastics. The directory classifies it as a unknown/inactive API with a synthetic source/manufacturing origin. Other names for this substance include Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride and hydrate (1:2:2). Its PubChem CID is 50990967.

CAS No 1277165-20-4
Molecular Formula C28H28Cl2F3N7O3
Molecular Weight 638.5 g/mol
Synonyms 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;dihydrate;dihydrochloride

Frequently Asked Questions